Detalhe da pesquisa
1.
Discovery of the first non-ATP competitive IGF-1R kinase inhibitors: advantages in comparison with competitive inhibitors.
Bioorg Med Chem Lett
; 21(8): 2224-8, 2011 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-21441024
2.
Discovery and Pharmacokinetic and Pharmacological Properties of the Potent and Selective MET Kinase Inhibitor 1-{6-[6-(4-Fluorophenyl)-[1,2,4]triazolo[4,3-b]pyridazin-3-ylsulfanyl]benzothiazol-2-yl}-3-(2-morpholin-4-ylethyl)urea (SAR125844).
J Med Chem
; 59(15): 7066-74, 2016 08 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-27355974
3.
The selective intravenous inhibitor of the MET tyrosine kinase SAR125844 inhibits tumor growth in MET-amplified cancer.
Mol Cancer Ther
; 14(2): 384-94, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25504634
4.
2-Chloro-3-pyridin-3-yl-5,6,7,8-tetrahydroindolizine-1-carboxamide (CMV423), a new lead compound for the treatment of human cytomegalovirus infections.
Antiviral Res
; 55(3): 413-24, 2002 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-12206879
5.
Design of potent IGF1-R inhibitors related to bis-azaindoles.
Chem Biol Drug Des
; 76(2): 100-6, 2010 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-20545947